Intracoronary Urokinase in Kawasaki Disease: Treatment and Prevention of Myocardial Infarction

Hirohisa Kato, Osamu Inoue, Eisei Ichinose, Teiji Akagi, Noboru Sato

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The main cause of death in Kawasaki disease is myocardial infarction due to thrombotic occlusion of a coronary aneurysm. Intracoronary thrombolytic treatment was performed in 15 patients with Kawasaki disease with giant coronary aneurysms. Three patients had acute myocardial infarction, four demonstrated silent myocardial infarction, three suffered chest pain and five did not show ischemia features but had massive thrombus in the coronary aneurysms. Urokinase was infused into the coronary aneurysms as a bolus of 8,000 to 10,000 units/kg via a catheter over 10 minutes. Partial but significant coronary recanalization was achieved after injection of urokinase in a patient with acute myocardial infarction. Complete resolution of massive intracoronary thrombi was observed in 3 of 15 patients, and partial resolution was recognized in 4 cases. In 7 patients, the size of thrombus did not change. Recurrence of the thrombus was observed in 4 patients by serial two‐dimensional echocardiography. Urokinase was readmmistered and two showed significant reduction in the thrombus. All patients have been followed for more than 2 years with longest 8 years (mean: 3.3 yrs), and none have had a recurrence of myocardial infarction or died. These findings suggest that intracoronary urokinase is useful for the treatment and prevention of myocardial infarction in Kawasaki disease.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalPediatrics International
Volume33
Issue number1
DOIs
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Mucocutaneous Lymph Node Syndrome
Urokinase-Type Plasminogen Activator
Coronary Aneurysm
Myocardial Infarction
Thrombosis
Therapeutics
Recurrence
Chest Pain
Echocardiography
Cause of Death
Ischemia
Catheters
Injections

Keywords

  • Coronary thrombosis
  • Intracoronary thrombolytic therapy
  • Kawasaki disease
  • Myocardial infarction
  • Percutaneous transluminal coronary revasculization (PTCR)
  • Urokinase

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Intracoronary Urokinase in Kawasaki Disease : Treatment and Prevention of Myocardial Infarction. / Kato, Hirohisa; Inoue, Osamu; Ichinose, Eisei; Akagi, Teiji; Sato, Noboru.

In: Pediatrics International, Vol. 33, No. 1, 1991, p. 27-35.

Research output: Contribution to journalArticle

Kato, Hirohisa ; Inoue, Osamu ; Ichinose, Eisei ; Akagi, Teiji ; Sato, Noboru. / Intracoronary Urokinase in Kawasaki Disease : Treatment and Prevention of Myocardial Infarction. In: Pediatrics International. 1991 ; Vol. 33, No. 1. pp. 27-35.
@article{7d42fdf340a74d23af968d50c2aa81b9,
title = "Intracoronary Urokinase in Kawasaki Disease: Treatment and Prevention of Myocardial Infarction",
abstract = "The main cause of death in Kawasaki disease is myocardial infarction due to thrombotic occlusion of a coronary aneurysm. Intracoronary thrombolytic treatment was performed in 15 patients with Kawasaki disease with giant coronary aneurysms. Three patients had acute myocardial infarction, four demonstrated silent myocardial infarction, three suffered chest pain and five did not show ischemia features but had massive thrombus in the coronary aneurysms. Urokinase was infused into the coronary aneurysms as a bolus of 8,000 to 10,000 units/kg via a catheter over 10 minutes. Partial but significant coronary recanalization was achieved after injection of urokinase in a patient with acute myocardial infarction. Complete resolution of massive intracoronary thrombi was observed in 3 of 15 patients, and partial resolution was recognized in 4 cases. In 7 patients, the size of thrombus did not change. Recurrence of the thrombus was observed in 4 patients by serial two‐dimensional echocardiography. Urokinase was readmmistered and two showed significant reduction in the thrombus. All patients have been followed for more than 2 years with longest 8 years (mean: 3.3 yrs), and none have had a recurrence of myocardial infarction or died. These findings suggest that intracoronary urokinase is useful for the treatment and prevention of myocardial infarction in Kawasaki disease.",
keywords = "Coronary thrombosis, Intracoronary thrombolytic therapy, Kawasaki disease, Myocardial infarction, Percutaneous transluminal coronary revasculization (PTCR), Urokinase",
author = "Hirohisa Kato and Osamu Inoue and Eisei Ichinose and Teiji Akagi and Noboru Sato",
year = "1991",
doi = "10.1111/j.1442-200X.1991.tb01516.x",
language = "English",
volume = "33",
pages = "27--35",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Intracoronary Urokinase in Kawasaki Disease

T2 - Treatment and Prevention of Myocardial Infarction

AU - Kato, Hirohisa

AU - Inoue, Osamu

AU - Ichinose, Eisei

AU - Akagi, Teiji

AU - Sato, Noboru

PY - 1991

Y1 - 1991

N2 - The main cause of death in Kawasaki disease is myocardial infarction due to thrombotic occlusion of a coronary aneurysm. Intracoronary thrombolytic treatment was performed in 15 patients with Kawasaki disease with giant coronary aneurysms. Three patients had acute myocardial infarction, four demonstrated silent myocardial infarction, three suffered chest pain and five did not show ischemia features but had massive thrombus in the coronary aneurysms. Urokinase was infused into the coronary aneurysms as a bolus of 8,000 to 10,000 units/kg via a catheter over 10 minutes. Partial but significant coronary recanalization was achieved after injection of urokinase in a patient with acute myocardial infarction. Complete resolution of massive intracoronary thrombi was observed in 3 of 15 patients, and partial resolution was recognized in 4 cases. In 7 patients, the size of thrombus did not change. Recurrence of the thrombus was observed in 4 patients by serial two‐dimensional echocardiography. Urokinase was readmmistered and two showed significant reduction in the thrombus. All patients have been followed for more than 2 years with longest 8 years (mean: 3.3 yrs), and none have had a recurrence of myocardial infarction or died. These findings suggest that intracoronary urokinase is useful for the treatment and prevention of myocardial infarction in Kawasaki disease.

AB - The main cause of death in Kawasaki disease is myocardial infarction due to thrombotic occlusion of a coronary aneurysm. Intracoronary thrombolytic treatment was performed in 15 patients with Kawasaki disease with giant coronary aneurysms. Three patients had acute myocardial infarction, four demonstrated silent myocardial infarction, three suffered chest pain and five did not show ischemia features but had massive thrombus in the coronary aneurysms. Urokinase was infused into the coronary aneurysms as a bolus of 8,000 to 10,000 units/kg via a catheter over 10 minutes. Partial but significant coronary recanalization was achieved after injection of urokinase in a patient with acute myocardial infarction. Complete resolution of massive intracoronary thrombi was observed in 3 of 15 patients, and partial resolution was recognized in 4 cases. In 7 patients, the size of thrombus did not change. Recurrence of the thrombus was observed in 4 patients by serial two‐dimensional echocardiography. Urokinase was readmmistered and two showed significant reduction in the thrombus. All patients have been followed for more than 2 years with longest 8 years (mean: 3.3 yrs), and none have had a recurrence of myocardial infarction or died. These findings suggest that intracoronary urokinase is useful for the treatment and prevention of myocardial infarction in Kawasaki disease.

KW - Coronary thrombosis

KW - Intracoronary thrombolytic therapy

KW - Kawasaki disease

KW - Myocardial infarction

KW - Percutaneous transluminal coronary revasculization (PTCR)

KW - Urokinase

UR - http://www.scopus.com/inward/record.url?scp=84995013311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995013311&partnerID=8YFLogxK

U2 - 10.1111/j.1442-200X.1991.tb01516.x

DO - 10.1111/j.1442-200X.1991.tb01516.x

M3 - Article

C2 - 1853711

AN - SCOPUS:84995013311

VL - 33

SP - 27

EP - 35

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 1

ER -